beta

ADAP

Adaptimmune Therapeutics plc

Adap

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-06-2018 08-02-2018 05-09-2018 03-15-2018 08-03-2017 05-10-2017
Actual EPS 0.05 -0.48 -0.24 -0.29 -0.24 -0.3
Consensus EPS -0.03 -0.28 -0.24 -0.25 -0.24 -0.24
Estimated EPS -0.03 -0.28 -0.24 -0.25 -0.24 -0.24
Number of Estimates 6 5 6 5 5 5
EPS Surprise $0.08 -$0.20 -$0.04 -$0.06

Stats

Summary

Adaptimmune Therapeutics PLC along with its subsidiaries is a clinical-stage biopharmaceutical company. It is engaged in novel cancer immunotherapy products based on its T-cell receptor platform.

Market Cap: 855 Million

Primary Exchange: Nasdaq Global Select

Website: http://www.adaptimmune.com

Shares Outstanding: 93.7 Million

Float: 61.3 Million

Dividend: 0.0 (0.0%)

Beta: 1.894462

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 1.59 Million

Ethical Flags

Animal testing

Longest drawdown: 886 trading days

From: 2015-06-16 To: 2018-12-14

Lowest Point:

Adaptimmune Therapeutics PLC (ADAP) CEO James Noble on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 14:37:14:000

Adaptimmune Therapeutics PLC (ADAP) Q3 2018 Earnings Conference Call November 6, 2018 08:00 AM ET Executives Juli Miller - Director of IR James Noble - CEO & Director Rafael Amado - Chief Medical Officer Adrian Rawcliffe - Chief Financial Officer Analysts Jonathan Cha… read more...

Adaptimmune Therapeutics PLC (ADAP) CEO James Noble on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 14:37:14:000

Adaptimmune Therapeutics PLC (ADAP) Q3 2018 Earnings Conference Call November 6, 2018 08:00 AM ET Executives Juli Miller - Director of IR James Noble - CEO & Director Rafael Amado - Chief Medical Officer Adrian Rawcliffe - Chief Financial Officer Analysts Jonathan Cha… read more...

Adaptimmune Therapeutics PLC (ADAP) CEO James Noble on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 14:37:14:000

Adaptimmune Therapeutics PLC (ADAP) Q3 2018 Earnings Conference Call November 6, 2018 08:00 AM ET Executives Juli Miller - Director of IR James Noble - CEO & Director Rafael Amado - Chief Medical Officer Adrian Rawcliffe - Chief Financial Officer Analysts Jonathan Cha… read more...

Adaptimmune beats by $0.05, beats on revenue

via: SeekingAlpha at 2018-11-06 07:34:55:000

Adaptimmune (NASDAQ: ADAP ): Q3 GAAP EPS of $0.01 beats by $0.05 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Adaptimmune beats by $0.05, beats on revenue

via: SeekingAlpha at 2018-11-06 07:34:55:000

Adaptimmune (NASDAQ: ADAP ): Q3 GAAP EPS of $0.01 beats by $0.05 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Adaptimmune beats by $0.05, beats on revenue

via: SeekingAlpha at 2018-11-06 07:34:55:000

Adaptimmune (NASDAQ: ADAP ): Q3 GAAP EPS of $0.01 beats by $0.05 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Shipping and Biotech top list of midday movers (10/22/2018)

via: SeekingAlpha at 2018-10-22 12:49:47:000

Gainers: ESEA +173% . JTPY +142% . TOPS +108% . NETE +64% . GLBS +54% . ARII +51% . DCIX +50% . PXS +40% . SINO +35% . NVMM +32% . More news on: Euroseas Ltd., JetPay Corporation, TOP Ships Inc., Stocks on the move, , Top stock market news, Read mo… read more...

Shipping and Biotech top list of midday movers (10/22/2018)

via: SeekingAlpha at 2018-10-22 12:49:47:000

Gainers: ESEA +173% . JTPY +142% . TOPS +108% . NETE +64% . GLBS +54% . ARII +51% . DCIX +50% . PXS +40% . SINO +35% . NVMM +32% . More news on: Euroseas Ltd., JetPay Corporation, TOP Ships Inc., Stocks on the move, , Top stock market news, Read mo… read more...

Shipping and Biotech top list of midday movers (10/22/2018)

via: SeekingAlpha at 2018-10-22 12:49:47:000

Gainers: ESEA +173% . JTPY +142% . TOPS +108% . NETE +64% . GLBS +54% . ARII +51% . DCIX +50% . PXS +40% . SINO +35% . NVMM +32% . More news on: Euroseas Ltd., JetPay Corporation, TOP Ships Inc., Stocks on the move, , Top stock market news, Read mo… read more...

Premarket losers include HAS and PHG on Q3 earnings; healthcare companies down on presenting data at ESMO

via: SeekingAlpha at 2018-10-22 09:20:58:000

ADAP -34% on disappointing SPEAR cell data. More news on: Adaptimmune Therapeutics plc, Aduro Biotech, Mirati Therapeutics, Inc., Stocks on the move, Top stock market news, , Read more … read more...

Premarket losers include HAS and PHG on Q3 earnings; healthcare companies down on presenting data at ESMO

via: SeekingAlpha at 2018-10-22 09:20:58:000

ADAP -34% on disappointing SPEAR cell data. More news on: Adaptimmune Therapeutics plc, Aduro Biotech, Mirati Therapeutics, Inc., Stocks on the move, Top stock market news, , Read more … read more...

Premarket losers include HAS and PHG on Q3 earnings; healthcare companies down on presenting data at ESMO

via: SeekingAlpha at 2018-10-22 09:20:58:000

ADAP -34% on disappointing SPEAR cell data. More news on: Adaptimmune Therapeutics plc, Aduro Biotech, Mirati Therapeutics, Inc., Stocks on the move, Top stock market news, , Read more … read more...

Adaptimmune down 37% premarket on disappointing SPEAR cell data

via: SeekingAlpha at 2018-10-22 09:03:03:000

Adaptimmune Therapeutics plc (NASDAQ: ADAP ) slumps 37% premarket on light volume on the heels of its announcement of initial data from the first two cohorts of its ongoing studies evaluating its MAGE-A10 and MAGE-A4 SPEAR T-cells. The results were presented at ESMO in Munich. … read more...

Adaptimmune down 37% premarket on disappointing SPEAR cell data

via: SeekingAlpha at 2018-10-22 09:03:03:000

Adaptimmune Therapeutics plc (NASDAQ: ADAP ) slumps 37% premarket on light volume on the heels of its announcement of initial data from the first two cohorts of its ongoing studies evaluating its MAGE-A10 and MAGE-A4 SPEAR T-cells. The results were presented at ESMO in Munich. … read more...

Adaptimmune down 37% premarket on disappointing SPEAR cell data

via: SeekingAlpha at 2018-10-22 09:03:03:000

Adaptimmune Therapeutics plc (NASDAQ: ADAP ) slumps 37% premarket on light volume on the heels of its announcement of initial data from the first two cohorts of its ongoing studies evaluating its MAGE-A10 and MAGE-A4 SPEAR T-cells. The results were presented at ESMO in Munich. … read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

via: SeekingAlpha at 2018-10-18 08:49:27:000

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

Week 39 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-24 01:53:18:000

Breakout Forecast Selections for Week 39: Market conditions generated a strong increase in positive breakout momentum this week and with little change in negative momentum. The positive momentum gauge moved higher to 65 up from a value of 39 at the end of last week. The yellow positive m… read more...

Week 39 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-24 01:53:18:000

Breakout Forecast Selections for Week 39: Market conditions generated a strong increase in positive breakout momentum this week and with little change in negative momentum. The positive momentum gauge moved higher to 65 up from a value of 39 at the end of last week. The yellow positive m… read more...

Week 39 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-24 01:53:18:000

Breakout Forecast Selections for Week 39: Market conditions generated a strong increase in positive breakout momentum this week and with little change in negative momentum. The positive momentum gauge moved higher to 65 up from a value of 39 at the end of last week. The yellow positive m… read more...

Week 38 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-17 05:36:25:000

Breakout Forecast Selections for Week 38: Market conditions have generated a slight decrease in both positive breakout momentum and negative momentum this week. The positive momentum gauge moved lower to 39, down from a value of 44 at the end of last week. The yellow positive momentum cond… read more...

Week 38 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-17 05:36:25:000

Breakout Forecast Selections for Week 38: Market conditions have generated a slight decrease in both positive breakout momentum and negative momentum this week. The positive momentum gauge moved lower to 39, down from a value of 44 at the end of last week. The yellow positive momentum cond… read more...

Week 38 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-17 05:36:25:000

Breakout Forecast Selections for Week 38: Market conditions have generated a slight decrease in both positive breakout momentum and negative momentum this week. The positive momentum gauge moved lower to 39, down from a value of 44 at the end of last week. The yellow positive momentum cond… read more...

Adaptimmune Therapeutics announces registered direct offering of ADSs

via: SeekingAlpha at 2018-09-05 08:27:50:000

Adaptimmune Therapeutics (NASDAQ: ADAP ) has entered into a definitive agreement with Matrix Capital Management Company, LP, New Enterprise Associates 16, L.P., New Enterprise Associates 14, L.P. and Syncona Portfolio Limited, to purchase an aggregate of US$100M of its American Depositary … read more...

Adaptimmune Therapeutics announces registered direct offering of ADSs

via: SeekingAlpha at 2018-09-05 08:27:50:000

Adaptimmune Therapeutics (NASDAQ: ADAP ) has entered into a definitive agreement with Matrix Capital Management Company, LP, New Enterprise Associates 16, L.P., New Enterprise Associates 14, L.P. and Syncona Portfolio Limited, to purchase an aggregate of US$100M of its American Depositary … read more...

Adaptimmune Therapeutics announces registered direct offering of ADSs

via: SeekingAlpha at 2018-09-05 08:27:50:000

Adaptimmune Therapeutics (NASDAQ: ADAP ) has entered into a definitive agreement with Matrix Capital Management Company, LP, New Enterprise Associates 16, L.P., New Enterprise Associates 14, L.P. and Syncona Portfolio Limited, to purchase an aggregate of US$100M of its American Depositary … read more...

Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-01 13:03:24:000

Breakout Forecast Selections for Week 36: Market conditions have generated a strong increase in positive breakout momentum and a decline negative momentum this week. The positive momentum gauge continues higher to 65 up from a value of 51 at the end of last week. The yellow positive mome… read more...

Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-01 13:03:24:000

Breakout Forecast Selections for Week 36: Market conditions have generated a strong increase in positive breakout momentum and a decline negative momentum this week. The positive momentum gauge continues higher to 65 up from a value of 51 at the end of last week. The yellow positive mome… read more...

Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-01 13:03:24:000

Breakout Forecast Selections for Week 36: Market conditions have generated a strong increase in positive breakout momentum and a decline negative momentum this week. The positive momentum gauge continues higher to 65 up from a value of 51 at the end of last week. The yellow positive mome… read more...

Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-01 13:03:24:000

Breakout Forecast Selections for Week 36: Market conditions have generated a strong increase in positive breakout momentum and a decline negative momentum this week. The positive momentum gauge continues higher to 65 up from a value of 51 at the end of last week. The yellow positive mome… read more...

Why Adaptimmune's Forward Momentum May Be The Perfect Entry Point

via: SeekingAlpha at 2018-08-18 05:41:55:000

Author's note: If you're a member of the Total Pharma Tracker , you can discuss this and other actionable ideas, in addition to gaining access to exclusive daily notes as part of "3 Things in Biotech," along with Avisol Capital Partners' investing I/O machine. Click that link to try a free t… read more...

Why Adaptimmune's Forward Momentum May Be The Perfect Entry Point

via: SeekingAlpha at 2018-08-18 05:41:55:000

Author's note: If you're a member of the Total Pharma Tracker , you can discuss this and other actionable ideas, in addition to gaining access to exclusive daily notes as part of "3 Things in Biotech," along with Avisol Capital Partners' investing I/O machine. Click that link to try a free t… read more...

Why Adaptimmune's Forward Momentum May Be The Perfect Entry Point

via: SeekingAlpha at 2018-08-18 05:41:55:000

Author's note: If you're a member of the Total Pharma Tracker , you can discuss this and other actionable ideas, in addition to gaining access to exclusive daily notes as part of "3 Things in Biotech," along with Avisol Capital Partners' investing I/O machine. Click that link to try a free t… read more...

Why Adaptimmune's Forward Momentum May Be The Perfect Entry Point

via: SeekingAlpha at 2018-08-18 05:41:55:000

Author's note: If you're a member of the Total Pharma Tracker , you can discuss this and other actionable ideas, in addition to gaining access to exclusive daily notes as part of "3 Things in Biotech," along with Avisol Capital Partners' investing I/O machine. Click that link to try a free t… read more...

3 Things In Biotech, August 16: Adaptimmune Lines Up Its MAGEs And Makes Some Progress

via: SeekingAlpha at 2018-08-16 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. CytoDyn gives a look at a potential future direction for its CCR5 antibody Company : C… read more...

3 Things In Biotech, August 16: Adaptimmune Lines Up Its MAGEs And Makes Some Progress

via: SeekingAlpha at 2018-08-16 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. CytoDyn gives a look at a potential future direction for its CCR5 antibody Company : C… read more...

Adaptimmune: Are We Set Up For A Rebound?

via: SeekingAlpha at 2018-08-06 07:36:18:000

On November 22, 2017, I shared my first article about Adaptimmune ( ADAP ) for my SA readers. At the time I was very favorable for their stock being a good investment. The stock was trading at the time for $8.11. In the interim the stock rose as high $14.62 before retreating to the current s… read more...

Adaptimmune: Are We Set Up For A Rebound?

via: SeekingAlpha at 2018-08-06 07:36:18:000

On November 22, 2017, I shared my first article about Adaptimmune ( ADAP ) for my SA readers. At the time I was very favorable for their stock being a good investment. The stock was trading at the time for $8.11. In the interim the stock rose as high $14.62 before retreating to the current s… read more...

Adaptimmune: Are We Set Up For A Rebound?

via: SeekingAlpha at 2018-08-06 07:36:18:000

On November 22, 2017, I shared my first article about Adaptimmune ( ADAP ) for my SA readers. At the time I was very favorable for their stock being a good investment. The stock was trading at the time for $8.11. In the interim the stock rose as high $14.62 before retreating to the current s… read more...

Adaptimmune Therapeutics PLC (ADAP) CEO James Noble on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-04 10:17:04:000

Adaptimmune Therapeutics PLC (ADAP) Q2 2018 Earnings Conference Call August 2, 2018 8:00 AM ET Executives Juli Miller - Director of IR James Noble - CEO & Director Rafael Amado - Chief Medical Officer Analysts Robyn Karnauskas - Citi Peter Lawson - SunTrust Robinson H… read more...

Adaptimmune Therapeutics PLC (ADAP) CEO James Noble on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-04 10:17:04:000

Adaptimmune Therapeutics PLC (ADAP) Q2 2018 Earnings Conference Call August 2, 2018 8:00 AM ET Executives Juli Miller - Director of IR James Noble - CEO & Director Rafael Amado - Chief Medical Officer Analysts Robyn Karnauskas - Citi Peter Lawson - SunTrust Robinson H… read more...

Adaptimmune EPS of -$0.08

via: SeekingAlpha at 2018-08-02 07:33:38:000

Adaptimmune (NASDAQ: ADAP ): Q2 EPS of -$0.08 may not be comparable to consensus of -$0.27. More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Adaptimmune EPS of -$0.08

via: SeekingAlpha at 2018-08-02 07:33:38:000

Adaptimmune (NASDAQ: ADAP ): Q2 EPS of -$0.08 may not be comparable to consensus of -$0.27. More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Adaptimmune's SPEAR cells pass safety review in NSCLC study; dose to be raised; shares up 1% premarket

via: SeekingAlpha at 2018-07-18 08:57:26:000

Adaptimmune Therapeutics plc (NASDAQ: ADAP ) is up 1% premarket on light volume after it announced a favorable review of the safety of 1B transduced SPEAR T-cells targeting MAGE-A10 in its non-small cell lung cancer (NSCLC) study. More news on: Adaptimmune Therapeutics plc, H… read more...

Adaptimmune's SPEAR cells pass safety review in NSCLC study; dose to be raised; shares up 1% premarket

via: SeekingAlpha at 2018-07-18 08:57:26:000

Adaptimmune Therapeutics plc (NASDAQ: ADAP ) is up 1% premarket on light volume after it announced a favorable review of the safety of 1B transduced SPEAR T-cells targeting MAGE-A10 in its non-small cell lung cancer (NSCLC) study. More news on: Adaptimmune Therapeutics plc, H… read more...

Adaptimmune's SPEAR cells pass safety review in NSCLC study; dose to be raised; shares up 1% premarket

via: SeekingAlpha at 2018-07-18 08:57:26:000

Adaptimmune Therapeutics plc (NASDAQ: ADAP ) is up 1% premarket on light volume after it announced a favorable review of the safety of 1B transduced SPEAR T-cells targeting MAGE-A10 in its non-small cell lung cancer (NSCLC) study. More news on: Adaptimmune Therapeutics plc, H… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

A Short Case For A Longer Term!

via: SeekingAlpha at 2018-06-20 11:10:51:000

New York Stock Exchange Staying The Course, Including Drawdowns, Within A Bull Market The stock market is recording new all-time highs. The market has been led by the Russell 2000 ( IWM ) small cap index, which achieved the milestone in May, after a 3-month period of weakness for stocks…. read more...

A Short Case For A Longer Term!

via: SeekingAlpha at 2018-06-20 11:10:51:000

New York Stock Exchange Staying The Course, Including Drawdowns, Within A Bull Market The stock market is recording new all-time highs. The market has been led by the Russell 2000 ( IWM ) small cap index, which achieved the milestone in May, after a 3-month period of weakness for stocks…. read more...

3 Things In Biotech, June 13: Ripples, Transitions, And A Hint At Something Important

via: SeekingAlpha at 2018-06-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

3 Things In Biotech, June 13: Ripples, Transitions, And A Hint At Something Important

via: SeekingAlpha at 2018-06-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

3 Things In Biotech, June 13: Ripples, Transitions, And A Hint At Something Important

via: SeekingAlpha at 2018-06-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

3 Things In Biotech, June 13: Ripples, Transitions, And A Hint At Something Important

via: SeekingAlpha at 2018-06-14 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed

via: SeekingAlpha at 2018-06-13 09:16:27:000

Last week, two major meetings for biotechnology and pharmaceutical companies occurred at the same time. The ASCO annual meeting, the biggest oncology event in North America, was held from June 1 to 5 in Chicago. The BIO International Convention 2018, hosted by the Biotechnology Innovation Org… read more...

Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

via: SeekingAlpha at 2018-05-31 16:08:11:000

Biotech Pulse Small caps, a speculative segment of the market as opposed to mid and large caps, has made new highs. Can biotechs be far behind? Last week, we further discussed the leading role that small caps have assumed in the article Small Caps Charge Augurs Well for the Stock Market … read more...

Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

via: SeekingAlpha at 2018-05-31 16:08:11:000

Biotech Pulse Small caps, a speculative segment of the market as opposed to mid and large caps, has made new highs. Can biotechs be far behind? Last week, we further discussed the leading role that small caps have assumed in the article Small Caps Charge Augurs Well for the Stock Market … read more...

Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

via: SeekingAlpha at 2018-05-31 16:08:11:000

Biotech Pulse Small caps, a speculative segment of the market as opposed to mid and large caps, has made new highs. Can biotechs be far behind? Last week, we further discussed the leading role that small caps have assumed in the article Small Caps Charge Augurs Well for the Stock Market … read more...

The Kite Killer - TapImmune And Marker Merger Challenge Gilead

via: SeekingAlpha at 2018-05-30 09:15:28:000

History could be repeating itself and TapImmune (TPIV) could be Kite 2.0. The TPIV merger with Marker Therapeutics strongly positions the company to take on market leader Gilead Sciences (GILD) which acquired Kite Pharma for $11.9 billion in August 2017. Before the GILD merger Kite Pharma w… read more...

The Kite Killer - TapImmune And Marker Merger Challenge Gilead

via: SeekingAlpha at 2018-05-30 09:15:28:000

History could be repeating itself and TapImmune (TPIV) could be Kite 2.0. The TPIV merger with Marker Therapeutics strongly positions the company to take on market leader Gilead Sciences (GILD) which acquired Kite Pharma for $11.9 billion in August 2017. Before the GILD merger Kite Pharma w… read more...

The Kite Killer - TapImmune And Marker Merger Challenge Gilead

via: SeekingAlpha at 2018-05-30 09:15:28:000

History could be repeating itself and TapImmune (TPIV) could be Kite 2.0. The TPIV merger with Marker Therapeutics strongly positions the company to take on market leader Gilead Sciences (GILD) which acquired Kite Pharma for $11.9 billion in August 2017. Before the GILD merger Kite Pharma w… read more...

Small Caps Charge, Augurs Well For The Stock Market

via: SeekingAlpha at 2018-05-22 10:11:12:000

Finally, Small Caps Lead the Charge It is the first time in over a year that small cap stocks have led the broader market to a new all-time high. This relative outperformance suggests something important. Markets don't turn over and change primary trends when small caps are making new all-… read more...

Don't Buy L Brands - Cramer's Lightning Round (5/15/18)

via: SeekingAlpha at 2018-05-16 06:37:13:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, May 15. Bullish Calls Consolidated Edison (ED): It's a buy on weakness. Buy American Electric Power (AEP) too as it's a high quality utility. Clorox (CLX): Buy half now and the other half when i… read more...

Don't Buy L Brands - Cramer's Lightning Round (5/15/18)

via: SeekingAlpha at 2018-05-16 06:37:13:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, May 15. Bullish Calls Consolidated Edison (ED): It's a buy on weakness. Buy American Electric Power (AEP) too as it's a high quality utility. Clorox (CLX): Buy half now and the other half when i… read more...

Don't Buy L Brands - Cramer's Lightning Round (5/15/18)

via: SeekingAlpha at 2018-05-16 06:37:13:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, May 15. Bullish Calls Consolidated Edison (ED): It's a buy on weakness. Buy American Electric Power (AEP) too as it's a high quality utility. Clorox (CLX): Buy half now and the other half when i… read more...

Don't Buy L Brands - Cramer's Lightning Round (5/15/18)

via: SeekingAlpha at 2018-05-16 06:37:13:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, May 15. Bullish Calls Consolidated Edison (ED): It's a buy on weakness. Buy American Electric Power (AEP) too as it's a high quality utility. Clorox (CLX): Buy half now and the other half when i… read more...

Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now

via: CNBC at 2018-05-15 18:47:00:000

No summary available. read more...

Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now

via: CNBC at 2018-05-15 18:47:00:000

No summary available. read more...

Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now

via: CNBC at 2018-05-15 18:47:00:000

No summary available. read more...

Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now

via: CNBC at 2018-05-15 18:47:00:000

No summary available. read more...

Biotechs Emerge Unscathed And Ready To Go!

via: SeekingAlpha at 2018-05-15 08:28:41:000

Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th… read more...

Biotechs Emerge Unscathed And Ready To Go!

via: SeekingAlpha at 2018-05-15 08:28:41:000

Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th… read more...

Biotechs Emerge Unscathed And Ready To Go!

via: SeekingAlpha at 2018-05-15 08:28:41:000

Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th… read more...

Biotechs Emerge Unscathed And Ready To Go!

via: SeekingAlpha at 2018-05-15 08:28:41:000

Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th… read more...

Adaptimmune Therapeutics' (ADAP) CEO James Noble on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-09 15:27:08:000

Adaptimmune Therapeutics plc (ADAP) Q1 2018 Results Earnings Conference Call May 09, 2018 08:00 AM ET Executives Juli Miller - Director, IR James Noble - CEO Helen Tayton-Martin - Chief Business Officer Adrian Rawcliffe - CFO Rafael Amado - Chief Medical Officer Gwen Binder… read more...

Adaptimmune Therapeutics' (ADAP) CEO James Noble on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-09 15:27:08:000

Adaptimmune Therapeutics plc (ADAP) Q1 2018 Results Earnings Conference Call May 09, 2018 08:00 AM ET Executives Juli Miller - Director, IR James Noble - CEO Helen Tayton-Martin - Chief Business Officer Adrian Rawcliffe - CFO Rafael Amado - Chief Medical Officer Gwen Binder… read more...

Adaptimmune EPS of -$0.04

via: SeekingAlpha at 2018-05-09 07:35:02:000

Adaptimmune (NASDAQ: ADAP ): Q1 EPS of -$0.04 may not be comparable to consensus of -$0.21. More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Adaptimmune EPS of -$0.04

via: SeekingAlpha at 2018-05-09 07:35:02:000

Adaptimmune (NASDAQ: ADAP ): Q1 EPS of -$0.04 may not be comparable to consensus of -$0.21. More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Small Caps: The Bright Spot In A Challenging Stock Market

via: SeekingAlpha at 2018-05-07 15:21:58:000

Market Pulse The stock market is unpredictable and volatile and investors are being administered a high dosage of these nerve-wracking reminders during 2018. The high volatility this year appears to feel like a punishment meted out for the low-volatility indulgences of a mellow 2017 when sto… read more...

Small Caps: The Bright Spot In A Challenging Stock Market

via: SeekingAlpha at 2018-05-07 15:21:58:000

Market Pulse The stock market is unpredictable and volatile and investors are being administered a high dosage of these nerve-wracking reminders during 2018. The high volatility this year appears to feel like a punishment meted out for the low-volatility indulgences of a mellow 2017 when sto… read more...

Institutional Top Ideas Series: Orbimed Advisors

via: SeekingAlpha at 2018-05-04 03:18:51:000

In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of… read more...

Institutional Top Ideas Series: Orbimed Advisors

via: SeekingAlpha at 2018-05-04 03:18:51:000

In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of… read more...

Portfolio Review: Continued Market Outperformance In Q1 2018

via: SeekingAlpha at 2018-04-15 00:25:16:000

Following the teaching of Philip Fisher - who is Warren Buffetts mentor - we maintain the core of the Integrated BioSci Investing (IBI) as a long-term oriented growth-investing community. Notwithstanding, we are cognizant of the needs to service our partners, who are in… read more...

Portfolio Review: Continued Market Outperformance In Q1 2018

via: SeekingAlpha at 2018-04-15 00:25:16:000

Following the teaching of Philip Fisher - who is Warren Buffetts mentor - we maintain the core of the Integrated BioSci Investing (IBI) as a long-term oriented growth-investing community. Notwithstanding, we are cognizant of the needs to service our partners, who are in… read more...

Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned

via: SeekingAlpha at 2018-04-13 09:17:12:000

Biotech Pulse When the market experiences rain, biotechs experience a thunderstorm. That's how volatility relates to biotechnology - one of the most promising and nerve-wracking industries in the stock market. As the market succumbed last week to the drumbeat of a tariff war, volatility sp… read more...

Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned

via: SeekingAlpha at 2018-04-13 09:17:12:000

Biotech Pulse When the market experiences rain, biotechs experience a thunderstorm. That's how volatility relates to biotechnology - one of the most promising and nerve-wracking industries in the stock market. As the market succumbed last week to the drumbeat of a tariff war, volatility sp… read more...

Rounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators

via: SeekingAlpha at 2018-04-13 00:14:18:000

Dont be afraid of buying on a war scare. Through the entire twentieth century, with a single exception, every time major war has broken out anywhere in the world or whenever American forces have become involved in any fighting, whatever, the American stock market has always plunged s… read more...

Week 7 Breakout Forecast:  Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-02-12 11:53:36:000

Breakout Forecast Selections for Week 7 Market conditions remain unfavorable again this week as the conditions have been since Week 5. Readers are strongly cautioned to minimize market exposure until the momentum gauge returns a positive market indicator. The Week 6 selections from last we… read more...

Week 7 Breakout Forecast:  Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-02-12 11:53:36:000

Breakout Forecast Selections for Week 7 Market conditions remain unfavorable again this week as the conditions have been since Week 5. Readers are strongly cautioned to minimize market exposure until the momentum gauge returns a positive market indicator. The Week 6 selections from last we… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Immune Design: Same Story, Cheaper Price

via: SeekingAlpha at 2018-02-08 10:52:31:000

According to its website : We are a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the bodys immune system to fight disease. 2017 was the first year Immune Design (NASDAQ: IMDZ ) shares steadily increased in value, rising as muc… read more...

Immune Design: Same Story, Cheaper Price

via: SeekingAlpha at 2018-02-08 10:52:31:000

According to its website : We are a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the bodys immune system to fight disease. 2017 was the first year Immune Design (NASDAQ: IMDZ ) shares steadily increased in value, rising as muc… read more...

Immune Design: Same Story, Cheaper Price

via: SeekingAlpha at 2018-02-08 10:52:31:000

According to its website : We are a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the bodys immune system to fight disease. 2017 was the first year Immune Design (NASDAQ: IMDZ ) shares steadily increased in value, rising as muc… read more...

Immune Design: Same Story, Cheaper Price

via: SeekingAlpha at 2018-02-08 10:52:31:000

According to its website : We are a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the bodys immune system to fight disease. 2017 was the first year Immune Design (NASDAQ: IMDZ ) shares steadily increased in value, rising as muc… read more...

Immune Design: Same Story, Cheaper Price

via: SeekingAlpha at 2018-02-08 10:52:31:000

According to its website : We are a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the bodys immune system to fight disease. 2017 was the first year Immune Design (NASDAQ: IMDZ ) shares steadily increased in value, rising as muc… read more...

Week 6 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-02-05 05:00:11:000

Breakout Forecast Selections for Week 6: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...

Week 5 Breakout Forecast:  Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-28 01:31:19:000

Breakout Forecast Selections for Week 5: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...

Week 5 Breakout Forecast:  Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-28 01:31:19:000

Breakout Forecast Selections for Week 5: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...

Week 5 Breakout Forecast:  Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-28 01:31:19:000

Breakout Forecast Selections for Week 5: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...

Week 5 Breakout Forecast:  Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-28 01:31:19:000

Breakout Forecast Selections for Week 5: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...

Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-21 02:53:39:000

Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...

After Hours Gainers / Losers (1/16/2018)

via: SeekingAlpha at 2018-01-16 17:35:29:000

Top gainers: JUNO +44.5% . VRS +10.3% . ADAP +7.9% . CEIX +7.5% . BLUE +7.1% . More news on: Juno Therapeutics, Verso Corporation, Adaptimmune Therapeutics plc, Stocks on the move, Read more … read more...

Adaptimmune (ADAP) Presents At 10th Annual Biotech Showcase 2018 - Slideshow

via: SeekingAlpha at 2018-01-08 14:24:40:000

The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this Read more … read more...

Nasdaq Biotech Index: 54 to be added, 15 removed

via: SeekingAlpha at 2017-12-11 07:45:08:000

Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...

Adaptimmune: Is Now The Time To Adopt This Stock For Your Stock Portfolio?

via: SeekingAlpha at 2017-11-24 05:29:39:000

Investing Thesis I follow several biotechnology companies based on my thinking they are on the cutting edge of new therapies. One aspect of investing in biotechs is the issue of timing your investment to maximize your potential return. The wait is often more than what you would hope, therefo… read more...

Biotech Forum Daily Digest: Behind Omeros' Blowout Results

via: SeekingAlpha at 2017-11-13 14:58:19:000

A cynic is a man who, when he smells flowers, looks around for a coffin . H.L. Mencken The high beta parts of the market continued to take it on the shin while the large cap indices remain placid last week. The S&P 500 and Dow posted small losses on the week as both … read more...

Adaptimmune's NY-ESO SPEAR T-cell therapy shows encouraging effect in synovial sarcoma pilot study

via: SeekingAlpha at 2017-11-09 10:18:45:000

Updated results from a pilot study assessing Adaptimmune Therapeutics' ( ADAP -0.6% ) NY-ESO SPEAR T-cells in patients with synovial sarcoma showed a positive effect. The data were presented at the annual CTOS meeting in Hawaii. More news on: Adaptimmune Therapeutics plc, GlaxoSmithKl… read more...

Adaptimmune Therapeutics' (ADAP) CEO James Noble on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-11-04 07:42:05:000

Adaptimmune Therapeutics Plc (ADAP) Q3 2017 Earnings Conference Call November 2, 2017 08:00 AM ET Executives Juli Miller - Media Relations James Noble - Chief Executive Officer Adrian Rawcliffe - Chief Financial Officer Helen Tayton Martin - Chief Business Officer Bill Bertr… read more...

Adaptimmune EPS of $0.00

via: SeekingAlpha at 2017-11-02 07:38:04:000

Adaptimmune (NASDAQ: ADAP ): Q3 EPS of $0.00 may not be comparable to consensus of -$0.23. More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Adaptimmune Therapeutics (ADAP) Presents At LEERINK Partners Roundtable Series On Rare Disease And Immuno-Oncology - Slideshow

via: SeekingAlpha at 2017-09-29 11:51:20:000

The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX